Setrusumab is a Monoclonal Antibody owned by Mereo Biopharma Group, and is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 is planned.
Setrusumab is an anti-sclerostin monoclonal antibody. Sclerostin is a protein, an inhibitor of osteoblastogenesis. It is a glycoprotein secreted by osteocytes. Sclerostin after secretion by osteocytes travels through osteocyte canaliculi to the bone surface where it binds to coreceptors LRP5 and LRP6. It prevents localization with frizzled protein and Wnt signaling, and thereby reducing osteoblastogenesis and bone formation.
The revenue for Setrusumab is expected to reach a total of $837m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Setrusumab NPV Report.
Setrusumab was originated by Novartis and MorphoSys and is currently owned by Mereo Biopharma Group. Ultragenyx Pharmaceutical is the other company associated in development or marketing of Setrusumab.
Setrusumab is under development for the treatment of osteogenesis imperfecta type I, III and IV (also known as Brittle bone syndrome). The drug candidate is administered intravenously through infusion. It is a fully humanized monoclonal antibody targeting sclerostin. It was also under development for hypophosphatasia (HPP), osteoporosis in postmenopausal women and chronic kidney disease.
Mereo Biopharma Group Overview
Mereo Biopharma Group is a specialty bio-pharmaceutical company. The company develops novel medicines for the treatment of rare and specialty diseases. It’s pipeline products include BPS-804, which is used for the treatment of brittle bone syndrome and BCT-197, and Etigilimab (MPH-313), which treats solid tumors. Mereo Biopharma Group also offers BGS-649, an orally active aromatase inhibitor developed for the treatment of obese men with hypogonadotropic hypogonadism and its Navicixizumab (OMP-305B83) is in Phase 1 clinical trial which treats platinum-resistant ovarian cancer. The company collaborates with biotechnology and pharmaceutical companies. Mereo Biopharma Group is headquartered in London, England, the UK.
The company reported revenues of (British Pounds) GBP36.5 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was GBP20.9 million in FY2021, compared to an operating loss of GBP37.6 million in FY2020. The net profit of the company was GBP12.7 million in FY2021, compared to a net loss of GBP163.6 million in FY2020.
Quick View – Setrusumab
|Highest Development Stage|